厄贝沙坦联合美托洛尔治疗高血压性心脏病的临床探究

赵海龙

（蒲城县中医院内科，陕西 渭南，715500）

浏览次数：124次 下载次数：370次

摘要：

目的 探究厄贝沙坦联合美托洛尔治疗高血压性心脏病的临床效果。方法 选取我院2015年4月至2017年4月收治的80例高血压性心脏病患者，依据治疗方法分为联合组（n=40）和单独组（n=40），单独组患者接受厄贝沙坦治疗，联合组 患者接受厄贝沙坦联合美托洛尔治疗，然后对两组患者的血压和NYHA 心功能分级、临床疗效进行统计分析。结果 治疗后，联合组患者的收缩压、舒张压均显著低于单独组（P<0.05）；NYHA 心功能分级玉级占比（77.50%）显著高于单独组（45.00%） （P<0.05）；治疗总有效率为97.50%，显著高于单独组的75.00%（P<0.05）。结论 厄贝沙坦联合美托洛尔治疗高血压性心脏病的临床效果较单独厄贝沙坦明显更好，能有效降低血压及心功能分级，提升临床疗效，值得在临床推广。

关键词：厄贝沙坦；美托洛尔；高血压性心脏病；心功能

中图分类号：R541.3文献标志码：A文章编号：2096-1413(2017)35-0026-02

Clinical study of irbesartan combined with metoprolol in the treatment of hypertensive heart disease
ZHAO Hai-long
(Internal Medicine Department, Traditional Chinese Medicine Hospital of Pucheng County, Weinan 715500, China)

ABSTRACT：Objective To explore the clinical effect of irbesartan combined with metoprolol in the treatment of hypertensive heart disease. Methods Eighty cases of patients with hypertensive heart disease in our hospital from April 2015 to April 2017 were selected, and according to the treatment methods, the patients were divided into combined group (n=40) and single group (n=40). The single group was treated with irbesartan alone, and the combined group received irbesartan combined with metoprolol, then the blood pressure, NYHA of heart functional classification and clinical efficacy were sta原 tistically analyzed in both groups. Results After treatment, in the combined group, the systolic and diastolic blood pressures were significantly lower than those in the single group (P<0.05); the proportion of NYHA cardiac function grade I in the combined group was 77.50% (31/40), which was significantly higher than 45.00% in the single group (P<0.05); the total effective rate of the combined group was 97.50%, which was significantly higher than 75.00% in the single group (P<0.05). Conclusion The clinical curative effect of irbesartan combined with metoprolol is more significant than that using irbesartan alone in the treatment of hypertensive heart disease, it can effectively reduce the blood pressure and heart function classification, and improve clinical curative effect, which is worthy of promotion.
KEYWORDS: irbesartan; metoprolol; hypertensive heart disease; cardiac function

参考文献：
[1] 龙文.厄贝沙坦联合硝苯地平控释片治疗高血压的效果[J].中国当 代医药,2014,7(23):76-80.
[2] 谭业蕙,黄齐亮.常用4 种抗高血压药治疗原发性高血压的成本-效果分析[J].中国医院用药评价与分析,2012,12(3):241-243.
[3] 李玲,宋夏,胡汉昆,等.非洛地平联合美托洛尔对比单用非洛地平 治疗高血压的疗效与安全性的Meta 分析[J].中国药房,2014,25(32):2987-2990.
[4] 王敏珍.依那普利联合美托洛尔治疗高血压的临床效果[J].中国当 代医药,2014,21(21):107-111.
[5] 王传花.应用美托洛尔联合稳心颗粒治疗高血压心脏病合并室性 早搏的疗效研究[J].当代医药论丛,2014,12(16):145-146.
[6] 陈锦林.美托洛尔联合稳心颗粒治疗高血压心脏病室性期前收缩 的疗效观察[J].实用心脑肺血管病杂志,2014,22(10):48-49.
[7] 李婷.卡维地洛联合厄贝沙坦治疗慢性心力衰竭的疗效及安全性 分析[J].中国医药科学,2013,3(19):202-203.
[8] 叶同兴.美托洛尔联合稳心颗粒治疗高血压心脏病室性期前收缩 的疗效观察[J].临床合理用药,2014,7(9):49-50.